Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism
Status:
Completed
Trial end date:
2019-06-21
Target enrollment:
Participant gender:
Summary
This is a randomized, double blind, placebo-controlled, parallel, multicenter research in
order to evaluate the effect of Shuxuetong injection in prevention of symptomatic or
asymptomatic new cerebral infarction within 10 days.
Subgroup study：Evaluate the role of advanced diagnostic technique in identifying potential
causes of Embolic Stroke of Undetermined Source (ESUS).
Phase:
Phase 4
Details
Lead Sponsor:
Beijing Tiantan Hospital Ministry of Science and Technology of the People´s Republic of China